Drug Repurposing in Cancer Therapy. Approaches and Applications

Table of Contents

1. Drug repurposing for cancer therapydan introduction
2. A ligand-centric approach to identify potential drugs for repurposing: case study with aurora kinase inhibitors
3. Machine learning strategies for identifying repurposed drugs for cancer therapy
4. Unveiling potential anticancer drugs through in silico drug repurposing approaches
5. Increasing opportunities of drug repurposing for treating breast cancer by the integration of molecular, histological, and systemic approaches
6. The success story of drug repurposing in breast cancer
7. A personalized medicine approach to drug repurposing for the treatment of breast cancer molecular subtypes
8. Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma
9. Stories of drug repurposing for pancreatic cancer treatmentdPast, present, and future
10. Animal models and in vivo investigations for drug repurposing in lung cancer
11. Identification of chemosensitizers by drug repurposing to enhance the efficacy of cancer therapy
12. Drugs repurposed to potentiate immunotherapy for cancer treatment
13. Nanoparticle-based formulation for drug repurposing in cancer treatment
14. Nanotechnological approaches in cancer: the role of celecoxib and disulfiram
15. Clinical trials on combination of repurposed drugs and anticancer therapies

Authors

Kenneth K.W. To Associate Professor, Chinese University of Hong Kong. Prof. Kenneth To is currently an Associate Professor in the Chinese University of Hong Kong. He received post-doctoral training at the National Cancer Institute, National Institute of Health, USA, investigating the mechanisms of multidrug resistance and cancer epigenetics. After he became an independent investigator, his research interests focus on the development of novel strategies to overcome drug resistance to classical cytotoxic anticancer drugs as well as molecular targeted cancer therapeutics. He has served as Guest Associate Editor (Frontiers in Oncology & Frontiers in Genetics), Consulting Editor (Pharmacology Research and Perspectives) and Editorial Board Member in 4 other journals in the fields of cancer research and pharmacology. He published more than 100 peer-reviewed articles in highly ranked scientific journals in cancer biology and pharmacology. William C.S. Cho Queen Elizabeth Hospital, Hong Kong. Dr. William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer researches. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of some universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr. Cho has published about 300 peer-reviewed papers (Lancet Oncology, Nature Communications, PNAS, etc.) covering cancer biomarkers, anti-cancer drugs, proteomics, microRNAs, Chinese medicine and over a dozen of books.